The long-term goal of Project Transform is to integrate the patient experience into lung cancer treatment, research, and policy.
The treatment landscape of non-small cell lung cancer (NSCLC) is rapidly evolving, with the development of genetically targeted therapies and immunotherapy. In 2015 and 2016 alone, the US Food and Drug Administration (FDA) approved seven new drugs for the treatment of NSCLC, one reapproval, and five new indications for an existing treatment. However, the side effects and toxicities of these treatments can be significant.
With the emergence of new treatment options for lung cancer, the complexity of treatment decisions for people living with lung cancer has increased. With these treatment options come unaddressed questions: What do patients really want from their treatment? Better quality of life? Extended survival? Other benefits?
With this in mind, LUNGevity launched Project Transform in partnership with Johns Hopkins School of Public Health, to focus on developing and applying novel methods (eg, discrete-choice experiments) to scientifically quantify patient preferences for the benefits and risks of treatments for lung cancer.
The results obtained from this initiative will be used to inform regulators, industry, and clinicians of the preferences of people living with lung cancer.
The objectives of Project Transform are:
- To develop novel stated-preference methods to measure treatment preferences of patients
- To document NSCLC patients’ perspectives as to what constitutes meaningful benefits, what acceptable benefit-risk tradeoffs are, and patient preference heterogeneity (eg, differences in treatment preferences based on histology and age)
- To disseminate the results of the preference study to lung cancer patients and other stakeholders in lung cancer research, treatment, and policy
Project Transform is governed by an external advisory committee:
- Jeff Allen, Friends of Cancer Research
- Joel Beetsch, Celgene
- Gideon Blumenthal, MD, FDA
- Philip Bonomi, MD, Rush University Medical Center
- Julie Brahmer, MD, Johns Hopkins School of Medicine
- Emuella Flood, ICON
- Susan Gorky, Celgene
- Cynthia Grossman, PhD, Faster Cures
- Frank Liu, Merck
- Linnea Olson, lung cancer advocate, blogger, and artist
- Salome Samant, MD, Merck
- Jamie Studts, PhD, University of Kentucky
- Michelle Vichnin, Merck